Clinical Trials Logo

Clinical Trial Summary

New tools are needed to 1) diagnose and 2) stage early esophageal squamous cell carcinoma (SCC) in order to improve outcomes of this frequent and lethal cancer. Optical coherence tomography (OCT) is an optical technique, which can image human tissue ex vivo and in vivo with a resolution around 30µm and with a depth of 1mm. Full-field optical coherence tomography (FFOCT) is a new modality, which allows to image an ex vivo specimen with a cellular resolution and to perform 3D reconstruction. This device has never been tested on esophageal specimens. Therefore, the aim of this non-interventional research is 1) to determine FFOCT diagnostic criteria for SCC and 2) to figure if FFOCT allows the staging of the depth of invasion in SCC. To achieve these goals, we will image ex vivo 10 specimens of endoscopic resection of SCC (endoscopic mucosal resection (EMR) and submucosal dissection (ESD)) using an FFOCT device and we will compare the results with histological analysis of these specimens.


Clinical Trial Description

General study methodology The study presents the following characteristics: - Observational - Non interventional imaging study - Single-centre - Not controlled - Prospective Tests and analysis CRF - Filled by the investigator - Data from the medical file of the patient Imaging - As standard of care - Before endoscopic resection the lesion will be characterized and pictures will be made using white light endoscopy, magnification techniques and electronic chromoendoscopy - Immediately after endoscopic resection, the specimen will be prepared, oriented and scanned using the FFOCT device (CE marking) - Imaging movies will be then reviewed by trained readers and compared to movies of healthy patients, findings will be described - Imaging movies will be compared to pathology slides Pathology - After scanning the specimen will be sent to pathology for analysis - The pathology slides will be scanned to be kept in the study record together with their interpretation Study schedule - Total length of study: 24 months - Methodology and regulatory: 6 months - Recruitment period: 1 year - Recruitment among the patients scheduled for the endoscopic procedure in the operative room - One single visit = inclusion the day of the procedure - No follow-up required - Analyses: 3 months - Paper writing: 3 months ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03467529
Study type Observational
Source Nantes University Hospital
Contact
Status Completed
Phase
Start date November 6, 2018
Completion date July 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Completed NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Phase 2
Recruiting NCT06036563 - Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Not yet recruiting NCT05023928 - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer Phase 1
Recruiting NCT03941626 - Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies Phase 1/Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT02988921 - MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy N/A
Completed NCT02979691 - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 Phase 2/Phase 3
Terminated NCT02797405 - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay N/A
Recruiting NCT03347630 - Pre-operative MRI of Esophagus Cancer N/A
Completed NCT00193141 - Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer Phase 2
Recruiting NCT05626309 - Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer N/A
Completed NCT05615129 - Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT04046575 - Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Phase 1
Recruiting NCT06126406 - Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors Phase 1
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Enrolling by invitation NCT06160557 - A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma